ES2691306T3 - Procedimientos y composiciones para detectar mutaciones en el gen PI3KCA (PIK3CA) humano - Google Patents
Procedimientos y composiciones para detectar mutaciones en el gen PI3KCA (PIK3CA) humano Download PDFInfo
- Publication number
- ES2691306T3 ES2691306T3 ES14709926.1T ES14709926T ES2691306T3 ES 2691306 T3 ES2691306 T3 ES 2691306T3 ES 14709926 T ES14709926 T ES 14709926T ES 2691306 T3 ES2691306 T3 ES 2691306T3
- Authority
- ES
- Spain
- Prior art keywords
- artificial sequence
- dna
- note
- source
- description
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 103
- 238000000034 method Methods 0.000 title claims description 24
- 108700026093 human PI3KCA Proteins 0.000 title description 17
- 108090000623 proteins and genes Proteins 0.000 title description 16
- 239000000203 mixture Substances 0.000 title description 7
- 102000053900 human PI3KCA Human genes 0.000 title description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 121
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 88
- 239000002773 nucleotide Substances 0.000 claims abstract description 73
- 102200085790 rs121913281 Human genes 0.000 claims abstract description 27
- 101150063858 Pik3ca gene Proteins 0.000 claims abstract description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 55
- 239000000523 sample Substances 0.000 claims description 32
- 108700028369 Alleles Proteins 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 18
- 102200085789 rs121913279 Human genes 0.000 claims description 17
- 102200085788 rs121913279 Human genes 0.000 claims description 16
- 102200085641 rs121913273 Human genes 0.000 claims description 15
- 102200085635 rs121913274 Human genes 0.000 claims description 15
- 102200085637 rs121913274 Human genes 0.000 claims description 15
- 102200085787 rs121913283 Human genes 0.000 claims description 15
- 102200085791 rs121913286 Human genes 0.000 claims description 15
- 102200085792 rs121913286 Human genes 0.000 claims description 15
- 102220197790 rs397517201 Human genes 0.000 claims description 15
- 102200085639 rs104886003 Human genes 0.000 claims description 14
- 102220197894 rs121913277 Human genes 0.000 claims description 14
- 102220006545 c.1035C>A Human genes 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 239000011541 reaction mixture Substances 0.000 claims description 11
- 239000013610 patient sample Substances 0.000 claims description 5
- 101100190564 Homo sapiens PIK3CA gene Proteins 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims description 2
- 102200066687 rs1554698949 Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 228
- 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 37
- 239000003795 chemical substances by application Substances 0.000 description 31
- 150000007523 nucleic acids Chemical class 0.000 description 22
- 102000039446 nucleic acids Human genes 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 19
- 230000003321 amplification Effects 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 238000011282 treatment Methods 0.000 description 13
- 238000001514 detection method Methods 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 108091007960 PI3Ks Proteins 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 5
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 5
- 241001123946 Gaga Species 0.000 description 5
- 238000007844 allele-specific PCR Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- -1 nucleoside triphosphate Chemical class 0.000 description 3
- 102220197892 rs121913284 Human genes 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 101150096316 5 gene Proteins 0.000 description 2
- 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 2
- 241001212017 Brana Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000012268 protein inhibitor Substances 0.000 description 2
- 229940121649 protein inhibitor Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- WKKCYLSCLQVWFD-UHFFFAOYSA-N 1,2-dihydropyrimidin-4-amine Chemical compound N=C1NCNC=C1 WKKCYLSCLQVWFD-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- PKFBJSDMCRJYDC-GEZSXCAASA-N N-acetyl-s-geranylgeranyl-l-cysteine Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CSC[C@@H](C(O)=O)NC(C)=O PKFBJSDMCRJYDC-GEZSXCAASA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 125000006487 butyl benzyl group Chemical group 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006303 immediate early viral mRNA transcription Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780017P | 2013-03-13 | 2013-03-13 | |
| US201361780017P | 2013-03-13 | ||
| PCT/EP2014/054766 WO2014140061A2 (en) | 2013-03-13 | 2014-03-12 | Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2691306T3 true ES2691306T3 (es) | 2018-11-26 |
Family
ID=50277211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14709926.1T Active ES2691306T3 (es) | 2013-03-13 | 2014-03-12 | Procedimientos y composiciones para detectar mutaciones en el gen PI3KCA (PIK3CA) humano |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140272961A1 (enExample) |
| EP (1) | EP2971075B1 (enExample) |
| JP (1) | JP6453781B2 (enExample) |
| CN (2) | CN105229171A (enExample) |
| CA (1) | CA2899712C (enExample) |
| ES (1) | ES2691306T3 (enExample) |
| WO (1) | WO2014140061A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201206486D0 (en) * | 2012-04-12 | 2012-05-30 | Sequessome Technology Holdings Ltd | Vesicular formulations and uses thereof |
| WO2018094569A1 (zh) * | 2016-11-22 | 2018-05-31 | 深圳华大基因研究院 | 多肽及其应用 |
| CN109913481B (zh) * | 2019-04-24 | 2020-04-03 | 无锡市第五人民医院 | PIK3CA基因g.179224821G＞A突变及其在乳腺癌辅助诊断中的应用 |
| KR102813811B1 (ko) * | 2020-03-27 | 2025-05-30 | 주식회사 젠큐릭스 | Pik3ca 돌연변이 검출용 조성물 및 이를 포함하는 키트 |
| CN111363827A (zh) * | 2020-04-30 | 2020-07-03 | 北京和合医学诊断技术股份有限公司 | 用于检测pik3ca基因突变的引物组及其应用方法 |
| CN114410790B (zh) * | 2022-01-27 | 2024-04-12 | 湖南大学 | 一种用于检测ctDNA的生物传感检测系统及其检测方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2663248T3 (es) * | 2004-03-02 | 2018-04-11 | The Johns Hopkins University | Mutaciones del gen de PIK3CA en cánceres humanos |
| GB2453173A (en) * | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| JP5624044B2 (ja) * | 2008-10-20 | 2014-11-12 | エフ．ホフマン−ラ ロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改善されたアレル−特異的増幅 |
| US20100286143A1 (en) * | 2009-04-24 | 2010-11-11 | Dora Dias-Santagata | Methods and materials for genetic analysis of tumors |
| US9238832B2 (en) * | 2009-12-11 | 2016-01-19 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids |
| EP3246332B1 (en) * | 2010-01-12 | 2019-07-10 | Siemens Healthcare Diagnostics Inc. | Oligonucleotides and methods for detecting pik3ca mutations |
| CN102234685B (zh) * | 2010-04-23 | 2014-08-27 | 益善生物技术股份有限公司 | 一种pik3ca基因突变检测液相芯片 |
| KR101825121B1 (ko) * | 2010-08-13 | 2018-02-06 | 주식회사 파나진 | Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｐｉｋ3ｃａ 돌연변이 검출 방법 및 키트 |
| JP6050820B2 (ja) * | 2011-09-23 | 2016-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 改良された対立遺伝子特異的ｐｃｒのためのｇ−クランプの使用 |
-
2014
- 2014-03-12 WO PCT/EP2014/054766 patent/WO2014140061A2/en not_active Ceased
- 2014-03-12 EP EP14709926.1A patent/EP2971075B1/en active Active
- 2014-03-12 CN CN201480013282.7A patent/CN105229171A/zh active Pending
- 2014-03-12 ES ES14709926.1T patent/ES2691306T3/es active Active
- 2014-03-12 CA CA2899712A patent/CA2899712C/en active Active
- 2014-03-12 JP JP2015562104A patent/JP6453781B2/ja active Active
- 2014-03-12 CN CN201810088883.4A patent/CN108130373A/zh active Pending
- 2014-03-12 US US14/205,751 patent/US20140272961A1/en not_active Abandoned
-
2016
- 2016-02-05 US US15/017,179 patent/US20160160297A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2899712A1 (en) | 2014-09-18 |
| JP2016510982A (ja) | 2016-04-14 |
| WO2014140061A3 (en) | 2014-10-30 |
| US20160160297A1 (en) | 2016-06-09 |
| EP2971075A2 (en) | 2016-01-20 |
| US20140272961A1 (en) | 2014-09-18 |
| EP2971075B1 (en) | 2018-08-15 |
| WO2014140061A2 (en) | 2014-09-18 |
| JP6453781B2 (ja) | 2019-01-16 |
| CA2899712C (en) | 2021-01-05 |
| CN105229171A (zh) | 2016-01-06 |
| CN108130373A (zh) | 2018-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2346589T3 (es) | Metodo para la deteccion de mutaciones en egfr en muestras de sagre. | |
| ES2691306T3 (es) | Procedimientos y composiciones para detectar mutaciones en el gen PI3KCA (PIK3CA) humano | |
| ES2978995T3 (es) | Detección de deleciones del exón 14 de MET | |
| CN103923975B (zh) | 一种检测egfr基因外显子19缺失突变的试剂盒和方法 | |
| ES2705573T3 (es) | Procedimientos y composiciones para detectar mutaciones en el gen EZH2 humano | |
| KR20130094342A (ko) | 인간 표피 성장 인자 수용체 유전자 내의 돌연변이를 탐지하기 위한 방법 및 조성물 | |
| WO2009133915A1 (ja) | 癌マーカー、それを用いた癌の評価方法および評価試薬 | |
| CN101351563A (zh) | 用于预测或监测病人对于ErbB受体药物的响应的方法 | |
| WO2016167317A1 (ja) | 遺伝子変異の検出方法 | |
| KR101825121B1 (ko) | Ｐｎａ 기반의 실시간 ｐｃｒ 클램핑을 이용한 ｐｉｋ3ｃａ 돌연변이 검출 방법 및 키트 | |
| JP2013523178A (ja) | Ｋｒａｓプライマーおよびプローブ | |
| EP3301186A1 (en) | Method, sequences, compositions and kit for detection of mutations in the htert | |
| JP6153758B2 (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
| ES2564674T3 (es) | Nuevas mutaciones complejas en el dominio quinasa del receptor del factor de crecimiento epidérmico | |
| EP2761299B1 (en) | Mutations in sf3b1 and chronic lymphocytic leukemia | |
| ES2294346T3 (es) | Rt-pcr en tiempo real novedosa para la deteccion sensible de multiples transcripciones del gen mage. | |
| JP5859970B2 (ja) | 腫瘍分類のためのｉｒ−ａ及びｉｒ−ｂの定量 | |
| US20180298442A1 (en) | Method and kit for making diagnosis of myocardial infarction | |
| HK1078328A1 (en) | Primer and kit of determining a chemotherapeutic regimen based on ercc1 expression | |
| HK1078328B (en) | Primer and kit of determining a chemotherapeutic regimen based on ercc1 expression | |
| WO2012115068A1 (ja) | 乳癌におけるｆｇｆｒ４変異体の検出法 | |
| HK1128497B (en) | Method for the detection of egfr mutations in blood samples | |
| HK1196160A (en) | Mutations in sf3b1 and chronic lymphocytic leukemia | |
| HK1196160B (en) | Mutations in sf3b1 and chronic lymphocytic leukemia |